Algert Global LLC Has $3.96 Million Stake in 10x Genomics $TXG

Key Points

• Algert Global LLC decreased its stake in 10x Genomics by 31.4%, now holding approximately $3.96 million worth of shares after selling 207,333 shares in Q1.
• Other institutional investors, including ARK Investment Management and Vanguard Group, have increased their positions in 10x Genomics, highlighting strong interest from major players.
• The company reported better-than-expected earnings with a revenue of $172.91 million in its latest quarterly results, significantly exceeding estimates.

Algert Global LLC cut its stake in 10x Genomics (NASDAQ:TXG - Free Report) by 31.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 453,287 shares of the company's stock after selling 207,333 shares during the period. Algert Global LLC owned 0.37% of 10x Genomics worth $3,957,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in TXG. GF Fund Management CO. LTD. acquired a new position in shares of 10x Genomics during the fourth quarter valued at $32,000. GAMMA Investing LLC increased its holdings in shares of 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after purchasing an additional 1,614 shares during the period. Signaturefd LLC increased its holdings in shares of 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after purchasing an additional 2,409 shares during the period. Whittier Trust Co. acquired a new stake in 10x Genomics in the first quarter worth approximately $41,000. Finally, PNC Financial Services Group Inc. lifted its position in 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock worth $45,000 after purchasing an additional 3,119 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TXG shares. Morgan Stanley cut their target price on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Tuesday, August 12th. Canaccord Genuity Group set a $16.00 target price on 10x Genomics in a research report on Monday, August 11th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research report on Thursday, August 14th. Bank of America upped their target price on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Thursday, June 26th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $13.54.

10x Genomics Stock Up 9.2%

Shares of 10x Genomics stock traded up $1.20 during trading on Friday, hitting $14.30. The stock had a trading volume of 3,446,087 shares, compared to its average volume of 3,399,679. The stock has a 50 day simple moving average of $12.59 and a 200 day simple moving average of $10.68. The company has a market capitalization of $1.78 billion, a PE ratio of -20.43 and a beta of 2.03. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm's quarterly revenue was up 12.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.